Etiology, Pathophysiology, and Treatment of Atrial Fibrillation Part 1

被引:18
作者
Arortow, Wilbert S. [1 ]
机构
[1] New York Med Coll, Westchester Med Ctr, Div Cardiol, Dept Med, Valhalla, NY 10595 USA
关键词
atrial fibrillation; beta blockers; stroke; cardiovascular disease; cardioversion; digoxin; calcium channel blockers; radiofrequency catheter ablation; pacemakers; antiarrhythmic drugs;
D O I
10.1097/CRD.0b013e31816de1e3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Atrial fibrillation (AF) is associated with a higher incidence of mortality, stroke, and coronary events than is sinus rhythm. AF with a rapid ventricular rate may cause a tachycardia-related cardiomyopathy. Immediate direct-current cardioversion should be performed in patients with AF and acute myocardial infarction, chest pain due to myocardial ischemia, hypotension, severe heart failure, or syncope. Intravenous beta blockers, verapamil, or diltiazem may be given to immediately slow a very rapid ventricular rate in AF. An oral beta blocker, verapamil, or diltiazem should be used in persons with AF if a fast ventricular rate occurs at rest or during exercise despite digoxin. Amiodarone may be used in selected patients with symptomatic life-threatening AF refractory to other drugs. Digoxin should not be used to treat patients with paroxysmal AF. Nonpharmacologic therapies should be used in patients with symptomatic AF in whom a rapid ventricular rate cannot be slowed by drugs. This is part 1 of a 2-part review of the etiology, pathophysiology, and treatment of atrial fibrillation. The second part will be published in the subsequent issue of Cardiology in Review.
引用
收藏
页码:181 / 188
页数:8
相关论文
共 50 条
  • [21] Pathophysiology of atrial fibrillation and chronic kidney disease
    Ding, Wern Yew
    Gupta, Dhiraj
    Wong, Christopher F.
    Lip, Gregory Y. H.
    CARDIOVASCULAR RESEARCH, 2021, 117 (04) : 1046 - 1059
  • [22] Pathophysiology and prevention of atrial fibrillation
    Allessie, MA
    Boyden, PA
    Camm, AJ
    Kléber, AG
    Lab, MJ
    Legato, MJ
    Rosen, MR
    Schwartz, PJ
    Spooner, PM
    Van Wagoner, DR
    Waldo, AL
    CIRCULATION, 2001, 103 (05) : 769 - 777
  • [23] Atrial fibrillation fact sheet in Korea 2024 (part 3): treatment for atrial fibrillation in Korea: medicines and ablation
    Yun Gi Kim
    Kwang-No Lee
    Yong-Soo Baek
    Bong-Seong Kim
    Kyung-Do Han
    Hyoung-Seob Park
    Jinhee Ahn
    Jin-Kyu Park
    Jaemin Shim
    International Journal of Arrhythmia, 25 (1)
  • [24] Atrial fibrillation (Part 2)
    Perrenoud, J. -J.
    EUROPEAN GERIATRIC MEDICINE, 2011, 2 (02) : 93 - 101
  • [25] Atrial fibrillation. Current recommendations for diagnosis and treatment
    Kirchhof, P.
    INTERNIST, 2013, 54 (05): : 583 - 593
  • [26] Diabetes mellitus and atrial fibrillation-from pathophysiology to treatment
    Leopoulou, Marianna
    Theofilis, Panagiotis
    Kordalis, Athanasios
    Papageorgiou, Nikolaos
    Sagris, Marios
    Oikonomou, Evangelos
    Tousoulis, Dimitris
    WORLD JOURNAL OF DIABETES, 2023, 14 (05) : 512 - 527
  • [27] Management of atrial fibrillation after cardiac surgery - Part I: Pathophysiology and risks
    Hill, LL
    Kattapuram, M
    Hogue, CW
    JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2002, 16 (04) : 483 - 494
  • [28] Treatment Complications of Atrial Fibrillation and Their Management
    Mattia, Allan
    Newman, Joshua
    Manetta, Frank
    INTERNATIONAL JOURNAL OF ANGIOLOGY, 2020, 29 (02) : 98 - 107
  • [29] New Insights in the Treatment of Atrial Fibrillation
    Meyer, C.
    Puererfellner, H.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2014, 139 (06) : 257 - 260
  • [30] Atrial fibrillation in hypertrophic cardiomyopathy: pathophysiology, diagnosis and management
    Falasconi, Giulio
    Pannone, Luigi
    Slavich, Massimo
    Margonato, Alberto
    Fragasso, Gabriele
    Spoladore, Roberto
    AMERICAN JOURNAL OF CARDIOVASCULAR DISEASE, 2020, 10 (04): : 409 - 418